Blood Product Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Red Blood Cells, Platelets, Fresh Frozen Plasma, White Blood Cells, and Others), By Application (Blood Station, Hospitals and Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 45.23 Billion
CAGR (2026-2031)	6.03%
Fastest Growing Segment	Red Blood Cells
Largest Market	North America
Market Size (2031)	USD 64.27 Billion

Market Overview

The Global Blood Product Market will grow from USD 45.23 Billion in 2025 to USD 64.27 Billion by 2031 at a 6.03% CAGR. Blood products encompass therapeutic biological substances fractionated from human blood, including whole blood, red blood cells, platelets, and plasma, which are vital for transfusion medicine and the treatment of hematological conditions. The market is primarily propelled by the increasing global prevalence of chronic diseases such as cancer and hemophilia, alongside an aging demographic that necessitates frequent surgical procedures and trauma management. These factors ensure a sustained demand for safe and compatible blood components across healthcare systems worldwide, independent of temporary market trends.

Despite this robust demand, the sector faces significant challenges related to supply chain sustainability and the reliability of voluntary donor pools. Severe shortages often disrupt availability, particularly during seasonal fluctuations or regional emergencies, creating substantial operational risks. According to America's Blood Centers, in 2025, approximately 25% of blood centers in the southern United States operated with a critical supply of one day or less. This statistic highlights the precarious nature of inventory maintenance which can impede consistent market expansion and patient access.

Key Market Drivers

The rising prevalence of hematological disorders and chronic diseases is a primary determinant of market trajectory, creating a sustained requirement for whole blood and fractionated components. As the incidence of conditions such as cancer and anemia accelerates, healthcare systems face increasing pressure to maintain robust inventories of red blood cells and platelets for supportive care and surgical interventions. For instance, according to the American Cancer Society, January 2025, in the 'Cancer Facts & Figures 2025' report, projections for prostate cancer alone reached 313,780 new cases in the United States, highlighting the expanding patient pool necessitating potential oncological surgeries and transfusion management. This epidemiological burden, particularly among aging demographics, ensures a continuous baseline demand for compatible blood products to manage intraoperative blood loss and chemotherapy-induced cytopenia, independent of seasonal supply fluctuations.

Simultaneously, the market is being reshaped by the surging demand for plasma-derived immunoglobulins, which have become essential for treating primary immunodeficiencies and autoimmune neuropathies. This segment significantly outpaces traditional whole-blood transfusions in value, driven by improved diagnostic rates and the expansion of approved indications for immunoglobulin therapies that require industrial-scale plasma fractionation. According to Biotech Dispatch, February 2025, in the 'Immunoglobulin sales drive a strong first half for CSL' article, CSL Behring reported immunoglobulin sales of $3.17 billion for the first half of the fiscal year, representing a 15% increase driven by global patient needs. This specific growth trajectory is indicative of the broader sector's vitality; indeed, according to Grifols, in February 2025, the company reported a total revenue increase of 10.3% for the full year 2024, confirming the robust financial expansion of the global blood product industry.

Download Free Sample Report

Key Market Challenges

The primary impediment to the growth of the Global Blood Product Market is the inherent volatility of supply chain sustainability and the unreliability of voluntary donor pools. Unlike manufactured pharmaceuticals, this market is tethered to human donation rates, creating a fragile ecosystem where availability often fails to meet robust clinical demand. This dependency creates substantial operational instability, as blood centers struggle to maintain consistent inventories required for critical treatments, thereby stalling revenue growth and market predictability. When collection rates dip, the entire value chain is disrupted, forcing the market to contract rather than expand.

This operational fragility is quantified by recent industrial statistics illustrating severe inventory deficits. According to the American Red Cross, in August 2024, the national blood supply plummeted by more than 25% in just one month due to seasonal donor disruptions. Such acute volatility forces healthcare systems to shift focus from service expansion to inventory rationing, directly hampering the market’s ability to scale. Consequently, the persistent misalignment between donor turnout and patient need acts as a hard ceiling on market progression, preventing the sector from fully capitalizing on the rising global demand for blood therapeutics.

Key Market Trends

The integration of Pathogen Reduction Technologies (PRT) is fundamentally altering market standards by preemptively neutralizing viruses, bacteria, and parasites in blood components, thereby mitigating the risk of transfusion-transmitted infections. This technology is increasingly standard for platelets and plasma, shifting the focus from reactive screening to proactive pathogen inactivation to ensure safety against emerging biological threats. Leading industry players are witnessing surged demand for these safety profiles, particularly for fibrinogen complexes used in hemorrhage control. According to Cerus Corporation, November 2025, in the 'Record Results for Third Quarter 2025' press release, the company reported total product revenue of $52.7 million, a 15% increase year-over-year, driven by the expanded commercial adoption of its INTERCEPT Blood System.

Simultaneously, the Widespread Adoption of Automated Blood Collection Systems is optimizing donor yield and operational efficiency, allowing centers to collect specific components like plasma or platelets in higher volumes than manual methods. These advanced apheresis platforms are critical for meeting the escalating global demand for plasma-derived therapies while offsetting donor pool constraints through improved collection velocity. This shift toward automated efficiency is evidenced by significant segmental growth in major collection franchises. According to Haemonetics Corporation, November 2025, in the 'Second Quarter Fiscal 2026 Earnings Release', the company's plasma business achieved an organic revenue growth of 19% (excluding strategic partner transitions), underscoring the rapid market uptake of its next-generation automated collection technologies.

Segmental Insights

The Red Blood Cells segment is recognized as the fastest-growing category in the Global Blood Product Market, fueled by the essential demand for transfusion therapies in critical care. This upward trend is chiefly driven by the rising incidence of trauma cases, complex surgical interventions, and chronic ailments such as anemia and cancer which require regular blood support. Additionally, the expanding geriatric population has significantly increased the need for these critical resources. The World Health Organization consistently highlights the urgent necessity for ensuring safe and sufficient blood stocks to address these medical burdens, further substantiating the segment's rapid growth.

Regional Insights

North America maintains a leading position in the Global Blood Product Market, driven by a high prevalence of hematological disorders and an established healthcare infrastructure. The region benefits from rigorous safety standards enforced by the U.S. Food and Drug Administration, which encourages consistent plasma collection and product development. Additionally, the presence of major industry players and a widespread network of donor centers supports a stable supply chain. These elements, combined with increasing demand for plasma-derived therapies, secure the region's primary standing in the global landscape.

Recent Developments

• In September 2024, Octapharma USA announced that the U.S. FDA had granted expanded approval for its fibrinogen concentrate, fibryga, to include the treatment of acquired fibrinogen deficiency. This condition is a serious complication often involving uncontrolled bleeding during major surgeries. The product, which is a lyophilized human fibrinogen powder, provides a rapid and precise alternative to cryoprecipitate, the traditional standard of care which requires thawing. This regulatory approval positions the company to better support critical care settings by offering a more efficient method for fibrinogen replacement, thereby improving management of severe bleeding episodes in surgical patients.
• In June 2024, Grifols strengthened its position in the global blood product market by securing U.S. FDA approval for YIMMUGO, an innovative intravenous immunoglobulin (IVIg) therapeutic. Developed by its subsidiary, this product is indicated for the treatment of patients with primary immunodeficiencies. The approval marks the first commercial entry into the United States for a product manufactured at the company's new, highly automated production facility in Germany. This development is part of the company’s broader strategy to expand its portfolio of plasma-derived medicines and increase the supply of essential immunoglobulins to meet growing patient demand globally.
• In June 2024, Takeda announced a strategic investment of $230 million to expand the production capacity for plasma-derived therapies at its manufacturing site in Los Angeles, California. This capital project constitutes one of the company's largest single investments in manufacturing infrastructure and is intended to significantly increase plasma fractionation capabilities. The expansion aims to address the rising global need for critical treatments for rare and chronic conditions, such as immunodeficiencies and bleeding disorders. By enhancing its domestic supply chain, the company plans to ensure a more reliable delivery of life-saving plasma products to patients while fostering sustainable growth in its operations.
• In April 2024, Pfizer Inc. achieved a significant regulatory milestone in the hemophilia sector with the U.S. Food and Drug Administration (FDA) approval of its gene therapy, BEQVEZ. This one-time treatment is indicated for adults with moderate to severe hemophilia B who currently use factor IX prophylaxis therapy or have a history of life-threatening hemorrhage. The approval was based on data from a pivotal Phase 3 study, which showed that the therapy enabled patients to produce factor IX endogenously, thereby reducing the burden of frequent infusions. This product launch represents a major advancement in the market, offering a transformative therapeutic option for eligible patients with this rare genetic bleeding disorder.

Key Market Players

• CSL Limited
• Takeda Pharmaceutical Company Limited
• Octapharma AG
• Grifols, S.A.
• Kedrion S.p.A
• Hualan Biological Vaccine Inc.
• Mitsubishi Tanabe Pharma Corporation
• Baxter International Inc.
• Versiti, Inc.
• Bio Products Laboratory Ltd.

By Type	By Application	By Region
Red Blood Cells Platelets Fresh Frozen Plasma White Blood Cells Others	Blood Station Hospitals and Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Blood Product Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Blood Product Market, By Type:

• Red Blood Cells
• Platelets
• Fresh Frozen Plasma
• White Blood Cells
• Others

• Blood Product Market, By Application:

• Blood Station
• Hospitals and Others

• Blood Product Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE